EPIX: First Patient Dosed in Combination Trial of EPI-7386 and Enzalutamide…
By David Bautz, PhD
NASDAQ:EPIX
READ THE FULL EPIX RESEARCH REPORT
ESSA Pharma Q1 EPS $(0.21) Down From $(0.20) YoY
ESSA Pharma (NASDAQ:EPIX) reported quarterly losses of $(0.21) per share. This is a 5 percent decrease over losses of $(0.20) per share from the same period last year.
70 Biggest Movers From Friday
Gainers
Everspin Technologies, Inc. (NASDAQ: MRAM) shares surged 63.2% to close at $10.74 on Friday after the company reported better-than-expected Q3 results and issued Q4 sales guidance above estimates.
ESSA Pharma, Caris Life Sciences Ink Liquid Biopsy Profiling Pact
Caris Life Sciences and ESSA Pharma Inc (NASDAQ:EPIX) have announced a Precision Development program to support ESSA’s development of EPI-7386 in metastatic castration-resistant…
Caris Life Sciences And ESSA Pharma Announce Liquid Biopsy Profiling Collaboration
Caris Life Sciences®, a molecular science company developing and delivering technologies to revolutionize healthcare, and ESSA Pharma Inc. (NASDAQ:EPIX) ("ESSA"), a clinical-stage pharmaceutical
EPIX: Unwarranted Selloff Following Phase 1 Trial Update
By David Bautz, PhD
NASDAQ:EPIX
READ THE FULL EPIX RESEARCH REPORT
46 Biggest Movers From Yesterday
Gainers
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares climbed 189.5% to close at $9.90 on Wednesday after surging over 15% on Tuesday.
Oppenheimer Maintains Outperform on ESSA Pharma, Lowers Price Target to $22
Oppenheimer analyst Mark Breidenbach maintains ESSA Pharma (NASDAQ:EPIX) with a Outperform and lowers the price target from $36 to $22.
60 Biggest Movers From Yesterday
Gainers
NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to expand product portfolio with introduction of Painshield relief for over-the-counter use and plans for future product launch.